Le Lézard
Classified in: Ebola virus, Health
Subject: ACC

Meda Aktiebolag Successfully Amends MTN Terms and Conditions and Exercises Call Option

SOLNA, Sweden, Dec. 6, 2017 /PRNewswire/ --

Meda Aktiebolag has successfully amended the terms and conditions of two series of notes issued pursuant to its SEK 7,000,000,000 medium term notes programme and inserted an early redemption call option which it will exercise with immediate effect

Today, Meda Aktiebolag (the "Company") held two noteholders' meetings pursuant to the summons sent on 7 November 2017 to the noteholders of the:

(i) SE0005132180 ? STIBOR 3M +2.85% 2013/2018 notes (the "2018 Notes"); and

(ii) SE0005991635 ? STIBOR 3M +1.65% 2014/2019 notes (the "2019 Notes" and together, with the 2018 Notes, the "Notes"),

issued under the SEK 7,000,000,000 medium term notes programme of the Company originally established on 25 May 2012 (as updated on 31 July 2012, 12 May 2014 and 16 July 2015), for the purposes of approving an amendment to the terms and conditions of the Notes to insert an early redemption call option (the "Call Option").

A sufficient number of noteholders were present in order for each noteholders' meeting to be quorate and a requisite majority of the voting noteholders at each noteholders meeting voted in favour of approving the proposed amendment to the terms and conditions.

As at the date hereof, the terms and conditions of the Notes have been effectively amended and the Company has given notice to the noteholders of each series of Notes that it will exercise the Call Option in accordance with the amended terms and conditions.

For further information regarding the amended terms and conditions and the Call Option, please refer to Skandinaviska Enskilda Banken AB (publ) acting as Tabulation and Paying Agent.

The Tabulation and Paying Agent:


Skandinaviska Enskilda Banken AB (publ)
Stjärntorget 4
SE-106 40 Stockholm
Tel: +46 (0)8 763 80 96
Email: sebtenderagent@seb.se
Attention: SEB Tender Agent


The Board of directors
Meda Aktiebolag

For further inquiries, please contact:

Melissa Trombetta,
Head of Global Investor Relations
Mylan NV.
Tel: +1(917)262-2958

This is information that Meda Aktiebolag is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 12:45 noon CET on 6 December 2017.

Meda Aktiebolag is a leading international specialty pharma company. Meda's products are sold in more than 120 countries worldwide and the company is represented by its own organizations in close to 60 countries. Find out more, visit www.meda.se.

This information was brought to you by Cision http://news.cision.com

The following files are available for download:


Press release (PDF)



These press releases may also interest you

13 déc 2018
Beleave Inc. ("Beleave" or the "Company") is pleased to announce that, following a detailed application and inspection process, it has received its Good Manufacturing Practices ("GMP") certification....

13 déc 2018
Canada House Wellness Group Inc. ("Canada House" or the "Company") is pleased to report its financial results for the three months ending October 31, 2018. All amounts are stated in thousands of Canadian dollars. Financial Highlights: Cash...

13 déc 2018
Extendicare Inc. ("Extendicare" or the "Company") announced that it has declared a cash dividend of C$0.04 per common share of the Company (the "Common Share") for the month of December 2018, which is payable on January 15, 2019 to shareholders of...

13 déc 2018
In the report the venous stents market, the market is expected to reach US$ $ 1,727.4 Mn in 2025 from US$ 829.0 in 2017. The market is estimated to grow with a CAGR of 9.7% from 2018-2025.Read the full report: https://www.reportlinker.com/p05653787...

13 déc 2018
The global surgical microscopes market is expected to reach US$ 1,452.4 Mn in 2025 from US$ 578.5 Mn in 2017. The surgical microscopes market is estimated to grow with a CAGR of 12.4% from 2018-2025.Read the full report:...

13 déc 2018
PEGylated Protein Therapeutics Market by Product Type (Colony Stimulating Factor, Interferon, Erythropoietin (EPO), Recombinant Factor VIII, Monoclonal Antibody, Enzyme, and Others) By Application (Cancer, Autoimmune Disease, Hepatitis, Multiple...

News published on 6 december 2017 at 07:16 and distributed by: